Final Program - American Society of Gene & Cell Therapy

More documents

Recommendations

Info

Program Schedule, Thursday, May 16, 2013 Oral Abstract Session 236 2:00 pm - 3:15 pm ROOM: 151 ABCG Physical Methods of Delivery CO-CHAIRS: King F. Kwong, MD and Kevin G. Rice, PhD (Abstracts 99 through 103; see page 95) Oral Abstract Session 237 3:05 pm - 4:05 pm ROOM: 150 ABC Evolution of Pulmonary Treatments CO-CHAIRS: Uta Griesenbach, PhD and Katherine J. Excoffon, PhD (Abstracts 104 through 107; Abstract 105 Withdrawn and Abstract 432 moved from Poster Session II; see pages 95-96) Oral Abstract Session 238 3:20 pm - 4:05 pm ROOM: 151 ABCG Immunologic & Host Responses in Gene & Cell Therapy CO-CHAIRS: Antonia Follenzi, MD, PhD and Federico Mingozzi, PhD (Abstracts 108 through 110; see page 96) Thursday, May 16, 2013 Exhibit Hall Open: Networking Reception & Poster Session I 4:00 pm - 6:00 pm ROOM: EXHIBIT HALL C/D AAV Vectors - I (Abstracts 111-125; see pages 96-97) Adenovirus and Other DNA Virus Vectors I (Abstracts 126-138; and Abstract 561 moved from Poster Session III; see pages 97-98) Physical Methods of Delivery (Abstracts 139-154; see pages 98-99) Chemical and Molecular Conjugates (Abstracts 155-165; Abstract 165 has been withdrawn from presentation; see page 99) Musculo-skeletal Gene & Cell Therapy I (Abstracts 166-182; see pages 99-100) Infectious Diseases and Vaccines (Abstracts 183-195; see pages 100-101) Cancer - Immunotherapy I (Abstracts 197-209; Abstract 196 withdrawn; see pages 101-102) Cancer-Targeted Gene & Cell Therapy: Viral Vector / siRNA-Mediated Therapies (Abstracts 210-221; see pages 102-103) Final Program SALT LAKE CITY, UTAH May 15–18, 2013 53
Program Schedule, Thursday, May 16, 2013 Sensory (Ophthalmic and Auditory) Gene & Cell Therapy (Abstracts 222-232; see page 103) Gene Regulation (Abstracts 233-246; see page 104) Fetal and Adult Stem Cells (Abstracts 247-258; Abstract 252 has been withdrawn from presentation; see pages 104-105) Cell Processing and Vector Production (Abstracts 259-265; see page 105) Late Breaking Abstracts I (Abstracts 677-700; Abstracts 687 and 698 Withdrawn from Presentation; see pages 105-107) Thursday, May 16, 2013 Canadian Attendee Reception 6:00 pm - 7:00 pm ROOM: 255 B Foundation Symposium 240 6:00 pm - 8:00 pm ROOM: BALLROOM B Gene and Cell Therapy for Cancer Supported by the Alliance for Cancer Gene Therapy. CO-CHAIRS: Xandra O. Breakeield, PhD and Savio L.C. Woo, PhD SPEAKERS Joseph C. Glorioso, III, PhD Targeted Cancer Therapies Cancer cell genetic analyses have identiied driver mutations that dysregulate cell proliferation- and differentiation-related pathways, providing focal points for targeting of cancer therapy. At least six targeting strategies have been employed: (i) the use of drugs that block different steps in cancer causing signaling cascades leading to the arrest of tumor cell growth and the induction of senescence, apoptosis and autophagy, (ii) application of drugs or immune mediators that attack the tumor microenvironment (iii) the use of antibodies that inhibit tumor cell growth by blocking growth factor receptors, (iv) coupling of therapeutics to antibodies, nanoparticles or other ligands that recognize tumor-associate antigens (v) immune based strategies to induce anti-tumor immunity, reduce immune down regulation or exploit engineered immune acting cells to destroy tumors, and (vi) the use of designer biologics such as viruses, bacteria or stem cells to selectively destroy tumors. Some notable successes will be highlighted for each of these approaches, however tumor heterogeneity makes it unlikely that any one strategy will succeed. Cancer virotherapy remains a very versatile strategy that takes advantage of advances in enhanced vector design to provide the most potent, highly selective tumor killers. Current methods to control vector transduction and transcription, evasion of innate immunity and enhanced vector replication and spread will be presented. Stephen J. Russell, MD, PhD Oncolytic Virotherapy Oncolytic viruses (OV) selectively destroy neoplastic tissue and it is theoretically possible to engineer or adapt any naturally occurring virus for this purpose; key engineering strategies will be reviewed. A spreading intratumoral OV infection can damage both infected and uninfected tumor cells; the mechanisms underlying both of these activities will be discussed. Oncolytic viruses can be combined with drugs or armed with transgenes to accelerate their spread, modulate their immunogenicity/potency or facilitate the noninvasive monitoring of their in vivo fate; illustrative examples will be discussed. Finally, several oncolytic viruses are currently being tested in clinical trials and the current status of this work will be summarized. 54 Final Program SALT LAKE CITY, UTAH May 15–18, 2013
Page 2 and 3:
ASGCT Officers and Board of Directo
Page 4 and 5: Annual Meeting Exhibitors - as of A
Page 6 and 7: Annual Meeting Supporters Patron Le
Page 8 and 9: Committee Rosters Advisory Council
Page 10 and 11: Committee Rosters Host Committee Ch
Page 12 and 13: Committee Rosters Program Committee
Page 14 and 15: Abstract Reviewers Cancer - Immunot
Page 16 and 17: Outstanding New Investigator Awards
Page 18 and 19: Faculty List Thomas W. Chalberg, Jr
Page 20 and 21: Faculty List Ann M. Leen, PhD Baylo
Page 22 and 23: Faculty List Evan Y. Snyder, MD PhD
Page 24 and 25: General Meeting Information Continu
Page 26 and 27: General Meeting Information Speaker
Page 28 and 29: Salt Palace Convention Center Floor
Page 30 and 31: Salt Palace Convention Center Floor
Page 32 and 33: Program Schedule, Wednesday, May 15
Page 48 and 49: Program Schedule, Thursday, May 16,
Page 60 and 61: Program Schedule, Friday, May 17, 2
Page 70 and 71: Program Schedule, Saturday, May 18,
Page 80 and 81: Exhibitor Descriptions Aldevron 323
Page 82 and 83: Exhibitor Descriptions HypOxygen 51
Page 84 and 85: Exhibitor Descriptions Panasonic He
Page 86 and 87: Exhibitor Descriptions University o
Page 88 and 89: Abstract Directory, Wednesday, May
Page 94 and 95: Abstract Directory, Thursday, May 1
Page 104 and 105:
Abstract Directory, Thursday, May 1
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Abstract Directory, Friday, May 17,
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Abstract Directory, Saturday, May 1
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Abstract Author Index Aartsma-Rus,
Page 142 and 143:
Abstract Author Index Bartel, Ronnd
Page 144 and 145:
Abstract Author Index Bridges, Char
Page 146 and 147:
Abstract Author Index Chicoine, Lou
Page 148 and 149:
Abstract Author Index Daukandt, Mar
Page 150 and 151:
Abstract Author Index Eleftheriadou
Page 152 and 153:
Abstract Author Index Furth, Mark E
Page 154 and 155:
Abstract Author Index Grosso, Chant
Page 156 and 157:
Abstract Author Index Hickey, Ray D
Page 158 and 159:
Abstract Author Index Jacobs, Edwin
Page 160 and 161:
Abstract Author Index Kildebeck, Er
Page 162 and 163:
Abstract Author Index Lankester, Ar
Page 164 and 165:
Abstract Author Index Ling, Changqu
Page 166 and 167:
Abstract Author Index Martin, Dougl
Page 168 and 169:
Abstract Author Index Morishita, Na
Page 170 and 171:
Abstract Author Index Okamoto, Sach
Page 172 and 173:
Abstract Author Index Potter, Phil
Page 174 and 175:
Abstract Author Index Ruggiero, Eli
Page 176 and 177:
Abstract Author Index Shirakawa, To
Page 178 and 179:
Abstract Author Index Swanson, Magd
Page 180 and 181:
Abstract Author Index Ugai, Hideyo.
Page 182 and 183:
Abstract Author Index Watts, Korash
Page 184 and 185:
Abstract Author Index Yanovich, Sau
show all

Final Program - American Society of Gene & Cell Therapy

Create successful ePaper yourself

Delete template?

Save as template?